Table 3 Patients with no progression in structural damage measured by Genant-modified Sharp scores in patients on abatacept therapy for 2 years

	Percentage of patients with no progression in structural damage*		Percentage of patients with no progression in structural damage in year 2†
Outcome	Baseline to year 1 (n = 328)	Baseline to year 2 (n = 324)	Non-progressors at end of year 1 remaining non-progressors†	Progressors at end of year 1 becoming non-progressors
Erosion (%)	61	56	83	49
Joint space narrowing (%)	74	68	87	52
Total (%)	56	50	79	45

All patients received background methotrexate.
*Defined by a change in the total score of ⩽0 from baseline to year 1. †Defined by a change in the total score of ⩽0 from year 1 to year 2.